Every 8-K that Vor Biopharma Inc. (VOR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. reported a board change, with Andrew Levin, M.D., Ph.D., resigning as a director effective July 6, 2026. His resignation was explicitly stated not to result from any disagreement with the company. The board expressed appreciation for his service.
On July 7, 2026, the board appointed David Zaccardelli, Pharm.D. as an independent Class II director to fill the vacancy, with a term running until the 2029 annual meeting of stockholders. He brings prior CEO and director experience at multiple public pharmaceutical companies that were later acquired.
For his board service, Dr. Zaccardelli will receive an annual cash retainer of $40,000 and an initial stock option grant covering up to 68,000 shares or options with a grant-date fair value of $700,000, plus ongoing annual option grants tied to either 34,000 shares or $350,000 in grant-date value.
Vor Biopharma Inc. reported results from its 2026 annual stockholder meeting and changes to its equity incentive plan. Stockholders approved an amended and restated 2021 Equity Incentive Plan that keeps the automatic annual share increase but now bases it on both issued and outstanding common shares and shares issuable from pre-funded warrants. The amended plan also provides that, unless an award agreement states otherwise, unvested time-based awards held by an employee will fully vest if the employee’s service ends due to death. Two Class II directors, Andrew Levin and Fouad Namouni, were re-elected, the equity plan amendment was approved, and Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026.
Vor Bio reported that its partner RemeGen has received decisions from China’s National Medicinal Products Administration for telitacicept in two autoimmune kidney and rheumatologic diseases. Telitacicept gained conditional approval for treating adult patients with IgA nephropathy and full approval for adult patients with Sjögren’s disease in China.
The IgA nephropathy decision is based on Phase 2 and Phase 3 data, including a 59% reduction in urinary protein-to-creatinine ratio at Week 39 with telitacicept 240 mg and a favorable safety profile. Telitacicept is described as the first and only BAFF/APRIL-targeting therapy approved for IgA nephropathy.
For Sjögren’s disease, a Phase 3 study showed statistically significant improvements in the ESSDAI disease activity score and clinically meaningful gains in the ESSPRI patient-reported index across 160 mg and 80 mg doses with sustained benefit to Week 48. Telitacicept is the first approved therapy for Sjögren’s disease in China. RemeGen controls development and commercialization in China, while Vor Bio holds exclusive rights outside Greater China and is advancing global Phase 3 programs.
Vor Biopharma Inc. entered into a securities purchase agreement with entities affiliated with TCGX for a private placement of 5,338,078 common shares at $14.05 per share, for gross proceeds of about $75.0 million. The closing is expected on or about March 30, 2026, subject to customary conditions.
After closing, Vor expects to have 54,185,582 common shares outstanding. The company plans to use the net proceeds to advance its clinical pipeline, including telitacicept programs, and for general corporate purposes. No placement agent was used. Vor also granted investors registration rights and will file a Form S-3 to register the resale of the new shares.
Vor Biopharma Inc. furnished an update on its financial position and upcoming investor outreach. For the fiscal year ended December 31, 2025, the company estimates that its cash, cash equivalents and short-term investments totaled approximately $450 million. This figure is preliminary, unaudited and may change once full year-end financial statements are completed and reviewed by the company’s independent registered public accounting firm.
Vor also highlighted its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, including a corporate presentation scheduled for January 13, 2026, from 10:30 a.m. to 11:10 a.m. PT at The Westin St. Francis, Georgian Room. The related investor presentation is available on the company’s website and attached as Exhibit 99.1, and the information is being furnished rather than filed under securities law provisions.
Vor Biopharma Inc. entered into a private securities purchase agreement with institutional investors to sell 13,876,032 shares of common stock at $10.81 per share, raising gross proceeds of about $150.0 million. The company plans to use the net proceeds to advance its clinical pipeline and for general corporate purposes.
Vor also agreed to a registration rights agreement requiring it to file a resale registration statement for these shares on Form S-3 and to seek effectiveness within set deadlines, with liquidated damages owed to investors if deadlines are missed. Separately, director Sarah Reed resigned, and the board appointed Andrew Levin as an independent Class II director and Wouter Joustra as an independent Class III director, with both receiving the standard non-employee director cash and equity compensation and entering into the company’s standard indemnification agreements.
Vor Biopharma Inc. announced a public equity offering of 10,000,000 shares at $10.00 per share. The Company expects net proceeds of approximately $93.7 million, or $107.8 million if underwriters exercise a 30-day option to purchase up to 1,500,000 additional shares, with closing expected on November 12, 2025, subject to customary conditions.
Vor plans to use proceeds to advance telitacicept clinical development, including initiation of a Phase 3 trial for primary Sjögren’s Disease, along with manufacturing, pre-commercialization, working capital and general corporate purposes. Including $49.8 million of net proceeds from recent ATM sales, the Company believes its cash resources will fund operations into the second quarter of 2027. Shares outstanding were 9,026,922 as of September 30, 2025.
Vor Biopharma (VOR) amended the employment agreement of Chief Development Officer Dr. Qing Zuraw, effective November 2, 2025, for a five‑month period. If she is terminated without cause, she will receive a lump-sum, pro‑rated portion of her 2025 target bonus and, if applicable, a pro‑rated portion of her 2026 target bonus. If she resigns for any reason after December 31, 2025, she will receive the same severance benefits as a without‑cause termination.
The company also announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer via a November 3, 2025 press release furnished under Regulation FD.
Vor Biopharma furnished a Regulation FD update via an 8-K. On October 28, 2025, the company hosted a webcast to discuss late‑breaking 48‑week Phase 3 clinical trial data from China for telitacicept in primary Sjögren’s disease. The presentation used in the webcast was furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
Vor Biopharma Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-20 reverse stock split. The Charter Amendment was approved by stockholders at the Company’s Special Meeting of Stockholders on August 25, 2025 and the amendment was filed with the Delaware Secretary of State on September 17, 2025. The filing is signed by Jean-Paul Kress, Chief Executive Officer. No other corporate changes, financings, or forward-looking guidance are disclosed in the provided text.
Vor Biopharma Inc. furnished a new corporate presentation to the investment community, dated September 2025, and made it available on its website. The materials are provided under Item 7.01 of a current report and are attached as Exhibit 99.1. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed under the securities laws and will only be incorporated into other filings if specifically referenced.
Vor Biopharma Inc. reported several changes to its Board of Directors. On August 25, 2025, director Joshua Resnick, M.D. resigned effective immediately, followed on August 26, 2025 by the immediate resignations of directors Matthew Patterson and David Lubner. The company states that each resignation was not due to any disagreement with the company, and the Board expressed appreciation for their years of service.
On August 27, 2025, the Board appointed Sarah Reed as an independent Class II director to fill the vacancy created by Dr. Resnick’s resignation, with a term running until the 2026 annual meeting of stockholders. Reed, age 61, is General Counsel of RA Capital Management, L.P. and has substantial legal and governance experience, including roles at Harvard Law School and the Harvard Yenching Institute. She will receive a $40,000 annual cash retainer and stock options to purchase 60,000 shares of common stock upon appointment, plus options for 30,000 shares at each future annual meeting starting in 2026, under the company’s standard non-employee director compensation policy.
Vor Biopharma Inc. filed an 8‑K reporting that its Board may implement a reverse stock split with a ratio anywhere between 1‑for‑5 and 1‑for‑30, with the final ratio to be determined at the Board's sole discretion. The filing includes a consent from Cooley LLP and notes that the cover page XBRL tags are embedded in the inline XBRL document. The report is dated August 27, 2025 and is signed by Jean‑Paul Kress, Chief Executive Officer.